Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wednesday, dashing remaining hopes that the widely used medication could help such patients.

The Danish drugmaker said last week that the trials, which were designed to show that its semaglutide pill Rybelsus could slow progression of the brain-wasting disease by at least 20%, did not meet their goals. The joint studies showed some improvement in a few key biological measures of the disease, but the changes were small and not enough to make a difference in delaying cognitive decline.

Both trials showed that Rybelsus had no impact at all on the rate of decline in a clinical dementia score compared

See Full Page